君实生物:特瑞普利单抗注射液第13项适应症上市申请获批

财中社
May 21

5月21日,君实生物(688180/01877)发布公告,近日公司收到《药品注册证书》,其特瑞普利单抗(商品名:拓益®)联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准,这是特瑞普利单抗注射液在中国内地获批的第13项适应症。  公告中提到,特瑞普利单抗注射液于2021年已获批用于晚期尿路上皮癌的二线及以上治疗,是我国首个获批的晚期尿路上皮癌非选择性人群...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10